References
Littlewood TJ et al. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865–2874
Leyland-Jones B ; BEST Investigators and Study Group (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncology 4: 459–460
Henke M et al. (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255–1260
Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Oncologic Drugs Advisory Committee. Minutes of the Meeting of Tuesday, May 4, 2004. [http://www.fda.gov/OHRMS/DOCKETS/ac/04/transcripts/4037T2.DOC] (Accessed 24 June 2005)
Acknowledgements
The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Steensma, D., Witzig, T. Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer?. Nat Rev Clin Oncol 2, 444–445 (2005). https://doi.org/10.1038/ncponc0283
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0283
- Springer Nature Limited